- Home
- MA vs ABBV Comparison
MA vs ABBV Comparison
Compare MA & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MA
- ABBV
- Stock Information
- Founded
- MA 1966
- ABBV 2012
- Country
- MA United States
- ABBV United States
- Employees
- MA N/A
- ABBV N/A
- Industry
- MA Business Services
- ABBV Biotechnology: Pharmaceutical Preparations
- Sector
- MA Consumer Discretionary
- ABBV Health Care
- Exchange
- MA Nasdaq
- ABBV Nasdaq
- Market Cap
- MA 495.7B
- ABBV 403.2B
- IPO Year
- MA 2006
- ABBV N/A
- Fundamental
- Price
- MA $544.62
- ABBV $233.81
- Analyst Decision
- MA Strong Buy
- ABBV Buy
- Analyst Count
- MA 26
- ABBV 20
- Target Price
- MA $647.31
- ABBV $236.47
- AVG Volume (30 Days)
- MA 2.6M
- ABBV 5.6M
- Earning Date
- MA 10-30-2025
- ABBV 10-31-2025
- Dividend Yield
- MA 0.56%
- ABBV 2.98%
- EPS Growth
- MA 18.23
- ABBV N/A
- EPS
- MA 15.64
- ABBV 1.32
- Revenue
- MA $31,474,000,000.00
- ABBV $59,644,000,000.00
- Revenue This Year
- MA $19.70
- ABBV $10.00
- Revenue Next Year
- MA $12.44
- ABBV $9.17
- P/E Ratio
- MA $34.89
- ABBV $175.95
- Revenue Growth
- MA 15.60
- ABBV 7.40
- 52 Week Low
- MA $465.59
- ABBV $163.81
- 52 Week High
- MA $601.77
- ABBV $244.81
- Technical
- Relative Strength Index (RSI)
- MA 38.07
- ABBV 61.44
- Support Level
- MA $548.01
- ABBV $216.15
- Resistance Level
- MA $565.91
- ABBV $239.29
- Average True Range (ATR)
- MA 10.17
- ABBV 5.31
- MACD
- MA 0.05
- ABBV 1.24
- Stochastic Oscillator
- MA 16.10
- ABBV 77.32
About MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to $10 trillion in volume during 2024. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.